What is the expected revenue from international market access efforts in the back half of 2023, assuming a national coverage decision (NCD) rate of 1.25 times that of CMS
en in the less number of days that they're sensing for.
We've got to continue to educate and create awareness around that potential. On the international side, I think of international, not as a significant driver of growth just yet. Obviously, the only place we're doing any meaningful business there right now is in the U.K., and that's still in a hyper-growth mode, but we're working through the scenario right now where we're trying to get put in place permanent reimbursement long term. We're still working underneath that AI award in that country.
Now we have started to target the private sector as well, which will bring with it some nice growth. But I think it's more of a let's wait and see how that plays out versus get out ahead of ourselves with respect to those expectations. I think longer term, international is going to be a meaningful contributor to overall growth for the company. But the reality is most of that is going to be a market access effort opening up opportunities over the course of this year and revenue probably doesn't really start to come from those efforts until the back half of 2023 most likely as we start to target new additional countries that we're going to take the product into.
I think for the year, international is going to be -- not going to be a huge driver of growth, but there will be a tremendous amount of opportunity going on there that sets it up for being a nice driver of growth into the future. 
David Rescott -- Truist Securities -- Analyst
OK. That's helpful. I guess just to clarify, the 20% plus growth rate is total blended growth for volumes, not specifically to Zio XT?
Doug Devine -- Chief Operating Officer and Chief Financial Officer
That's right.
David Rescott -- Truist Securities -- Analyst
OK. I guess just on the commercial front, I know you've always talked about in the past how there is the thought that commercial payors may ultimately adjust their rates based on what the NCD rate comes out to be. If we think about a rate in 2023 from NCD regardless of where that rate is or direction of where that rate goes, do you think the commercial payors at this point would shift their rates toward a national coverage decision, whether it's one and a half or 1.25 times that of CMS? Or do you think that commercial payors at this point likely have determined the rates at which they would continue to maintain on a go-forward basis and just after there is an NCD? 
Quentin Blackford -- President and Chief Executive Officer
Yeah. My view is, generally speaking, the commercial payers understand the value of this product. And they've consistently looked at this product differently than what CMS or the MACs had done historically. Now I do think CMS and the MACs are coming around to understand it differently than what they had historically, and you hear that now in those conversations with those parties where they will describe the Zio product for example as being very different than traditional Holter monitors.
We know that CMS and the MACs have come around to look at this a little bit differently. And I think the commercial payors have always sort of taken the position from the very beginning that they see us differently. And that's why you didn't see them make any drastic reaction to the CMS or the MAC rates in the past. They were clear that they thought that CMS and the MACs would come around to see this in a different light, and I think that's what we've seen.
I believe commercial payors, again, they understand the value for what it is. I don't see a lot of significant concerns around getting a national rate locked in and then seeing pressure on the commercial business. That's just not the way the majority of those discussions are going. Are there a couple of commercial payors here there who might peg their rate directly to the CMS? There are, but those are not significant volumes and significant payors for the most part.
And I feel like we've navigated that very well historically. The other thing that I think is interesting, and we'll spend more time talking about this into the future, but I'
en in the less number of days that they're sensing for.
We've got to continue to educate and create awareness around that potential. On the international side, I think of international, not as a significant driver of growth just yet. Obviously, the only place we're doing any meaningful business there right now is in the U.K., and that's still in a hyper-growth mode, but we're working through the scenario right now where we're trying to get put in place permanent reimbursement long term. We're still working underneath that AI award in that country.
Now we have started to target the private sector as well, which will bring with it some nice growth. But I think it's more of a let's wait and see how that plays out versus get out ahead of ourselves with respect to those expectations. I think longer term, international is going to be a meaningful contributor to overall growth for the company. But the reality is most of that is going to be a market access effort opening up opportunities over the course of this year and revenue probably doesn't really start to come from those efforts until the back half of 2023 most likely as we start to target new additional countries that we're going to take the product into.
I think for the year, international is going to be -- not going to be a huge driver of growth, but there will be a tremendous amount of opportunity going on there that sets it up for being a nice driver of growth into the future. 
David Rescott -- Truist Securities -- Analyst
OK. That's helpful. I guess just to clarify, the 20% plus growth rate is total blended growth for volumes, not specifically to Zio XT?
Doug Devine -- Chief Operating Officer and Chief Financial Officer
That's right.
David Rescott -- Truist Securities -- Analyst
 OK. I guess just on the commercial front, I know you've always talked about in the past how there is the thought that commercial payors may ultimately adjust their rates based on what the NCD rate comes out to be. If we think about a rate in 2023 from NCD regardless of where that rate is or direction of where that rate goes, do you think the commercial payors at this point would shift their rates toward a national coverage decision, whether it's one and a half or 1.25 times that of CMS? Or do you think that commercial payors at this point likely have determined the rates at which they would continue to maintain on a go-forward basis and just after there is an NCD? 
Quentin Blackford -- President and Chief Executive Officer
Yeah. My view is, generally speaking, the commercial payers understand the value of this product. And they've consistently looked at this product differently than what CMS or the MACs had done historically. Now I do think CMS and the MACs are coming around to understand it differently than what they had historically, and you hear that now in those conversations with those parties where they will describe the Zio product for example as being very different than traditional Holter monitors.
We know that CMS and the MACs have come around to look at this a little bit differently. And I think the commercial payors have always sort of taken the position from the very beginning that they see us differently. And that's why you didn't see them make any drastic reaction to the CMS or the MAC rates in the past. They were clear that they thought that CMS and the MACs would come around to see this in a different light, and I think that's what we've seen.
I believe commercial payors, again, they understand the value for what it is. I don't see a lot of significant concerns around getting a national rate locked in and then seeing pressure on the commercial business. That's just not the way the majority of those discussions are going. Are there a couple of commercial payors here there who might peg their rate directly to the CMS? There are, but those are not significant volumes and significant payors for the most part.
And I feel like we've navigated that very well historically. The other thing that I think is interesting, and we'll spend more time talking about this into the future, but I'